|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/30/24 New Enterprise Associates 13 LP SC 13D/A 1:89K Rhythm Pharmaceuticals, Inc. Go2 EDGAR SOLUTIONS… /FA Forest Baskett Nea 13 GP, Ltd Nea Partners 13, L.P. Patrick J. Kerins Scott D. Sandell |
Document/Exhibit Description Pages Size
1: SC 13D/A New Enterprise Associates 13, Lp (Rhythm HTML 88K
Pharmaceuticals) - Schedule 13D/A(#2E)
| Schedule 13D |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Rhythm Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $.001 par value
(Title of Class of Securities)
(CUSIP Number)
Stephanie Brecher
New Enterprise Associates
1954 Greenspring Drive, Suite 600, Timonium, MD 21093
(410) 842-4000
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 76243J105 |
13D | Page 2 of 7 Pages |
| Item 1. | Security and Issuer. |
This Amendment No. 2 to Schedule 13D amends and supplements the Schedule 13D originally filed on October 13, 2017, and Amendment No. 1 filed on March 29, 2023, and relates to the common stock, $.001 par value (the “Common Stock”) of Rhythm Pharmaceuticals, Inc. (the “Issuer”) having its principal executive office at 222 Berkeley Street, 12th Floor, Boston, MA 02116.
Certain terms used but not defined in this Amendment No. 2 have the meanings assigned thereto in the Schedule 13D (and Amendment No. 1 thereto). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D (and Amendment No. 1 thereto).
| Item 2. | Identity and Background. |
This statement is being filed by:
(a) New Enterprise Associates 13, L.P. (“NEA 13”); NEA Partners 13, L.P. (“NEA Partners 13”), which is the sole general partner of NEA 13; and NEA 13 GP, LTD (“NEA 13 LTD” and together with NEA Partners 13, the “Control Entities”), which is the sole general partner of NEA Partners 13; and
(b) Forest Baskett (“Baskett”), Patrick J. Kerins (“Kerins”) and Scott D. Sandell (“Sandell”) (together, the “Directors”). The Directors are the directors of NEA 13 LTD.
The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”
The address of the principal business office of NEA 13, each Control Entity, Sandell and Kerins is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025.
The principal business of NEA 13 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 13 is to act as the sole general partner of NEA 13. The principal business of NEA 13 LTD is to act as the sole general partner of NEA Partners 13. The principal business of each of the Directors is to manage the Control Entities, NEA 13 and a number of affiliated partnerships with similar businesses.
During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
NEA 13 and NEA Partners 13 are exempted limited partnerships organized under the laws of the Cayman Islands. NEA 13 LTD is an exempted company organized under the laws of the Cayman Islands. Each of the Directors is a United States citizen.
CUSIP No. 76243J105 |
13D | Page 3 of 7 Pages |
| Item 3. | Source and Amount of Funds or Other Consideration. |
Not applicable.
| Item 4. | Purpose of Transaction. |
Not applicable.
| Item 5. | Interest in Securities of the Issuer. |
As of November 1, 2023, each of the Reporting Persons ceased to beneficially own five percent (5%) or more of the Issuer’s Common Stock. This Amendment No. 2 was triggered solely due to a change in the number of outstanding shares of the Issuer’s Common Stock.
| Item 6. | Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer. |
Not applicable.
| Item 7. | Material to be Filed as Exhibits. |
Exhibit 1 – Agreement regarding filing of joint Schedule 13D.
CUSIP No. 76243J105 |
13D | Page 4 of 7 Pages |
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
EXECUTED this 30th day of April, 2024.
NEW ENTERPRISE ASSOCIATES 13, L.P.
| By: | NEA PARTNERS 13, L.P. General Partner |
| By: | NEA 13 GP, LTD General Partner |
By: *
Scott D. Sandell
Director
NEA PARTNERS 13, L.P.
| By: | NEA
13 GP, LTD General Partner |
By: *
Scott D. Sandell
Director
NEA 13 GP, LTD
By: *
Scott D. Sandell
Director
*
Forest Baskett
*
Patrick J. Kerins
*
Scott D. Sandell
*/s/ Zachary Bambach
Zachary Bambach
As attorney-in-fact
This Amendment No. 2 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.
CUSIP No. 76243J105 |
13D | Page 5 of 7 Pages |
AGREEMENT
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Rhythm Pharmaceuticals, Inc.
EXECUTED this 30th day of April, 2024.
NEW ENTERPRISE ASSOCIATES 13, L.P.
| By: | NEA PARTNERS 13, L.P. General Partner |
| By: | NEA 13 GP, LTD General Partner |
By: *
Scott D. Sandell
Director
NEA PARTNERS 13, L.P.
| By: | NEA
13 GP, LTD General Partner |
By: *
Scott D. Sandell
Director
NEA 13 GP, LTD
By: *
Scott D. Sandell
Director
*
Forest Baskett
*
Patrick J. Kerins
*
Scott D. Sandell
*/s/ Zachary Bambach
Zachary Bambach
As attorney-in-fact
This Agreement relating to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.
CUSIP No. 76243J105 |
13D | Page 6 of 7 Pages |
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), including, but not limited to, signing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney is perpetual, unless revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 29th day of February, 2024.
| /s/ Peter J. Barris | |
| Peter J. Barris | |
| /s/ Forest Baskett | |
| Forest Baskett | |
| /s/ Ali Behbahani | |
| Ali Behbahani | |
| /s/ Ronald D. Bernal | |
| Ronald D. Bernal | |
| /s/ Ann Bordetsky | |
| Ann Bordetsky | |
| /s/ Carmen Chang | |
| Carmen Chang | |
| /s/ Philip Chopin | |
| Philip Chopin | |
| /s/ Anthony A. Florence, Jr. | |
| Anthony A. Florence, Jr. | |
| /s/ Jonathan Golden | |
| Jonathan Golden | |
| /s/ Scott Gottlieb | |
| Scott Gottlieb |
CUSIP No. 76243J105 |
13D | Page 7 of 7 Pages |
| /s/ Mark Hawkins | |
| Mark Hawkins | |
| /s/ Jeffrey R. Immelt | |
| Jeffrey R. Immelt | |
| /s/ Aaron Jacobson | |
| Aaron Jacobson | |
| /s/ Patrick J. Kerins | |
| Patrick J. Kerins | |
| /s/ Hilarie Koplow-McAdams | |
| Hilarie Koplow-McAdams | |
| /s/ Vanessa Larco | |
| Vanessa Larco | |
| /s/ Julio C. Lopez | |
| Julio C. Lopez | |
| /s/ Tiffany Le | |
| Tiffany Le | |
| /s/ Mohamad H. Makhzoumi | |
| Mohamad H. Makhzoumi | |
| /s/ Edward T. Mathers | |
| Edward T. Mathers | |
| /s/ Gregory Papadopoulos | |
| Gregory Papadopoulos | |
| /s/ Kavita Patel | |
| Kavita Patel | |
| /s/ Scott D. Sandell | |
| Scott D. Sandell | |
| /s/ A. Brooke Seawell | |
| A. Brooke Seawell | |
| /s/ Peter Sonsini | |
Peter Sonsini |
|
| /s/ Melissa Taunton | |
| Melissa Taunton | |
| /s/ Paul E. Walker | |
| Paul E. Walker | |
| /s/ Rick Yang | |
| Rick Yang |
| This ‘SC 13D/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/30/24 | |||
| 11/1/23 | ||||
| 3/29/23 | 4, SC 13D/A | |||
| 10/13/17 | SC 13D | |||
| List all Filings | ||||